216 related articles for article (PubMed ID: 33500573)
1. Cancer research needs a better map.
Boehm JS; Garnett MJ; Adams DJ; Francies HE; Golub TR; Hahn WC; Iorio F; McFarland JM; Parts L; Vazquez F
Nature; 2021 Jan; 589(7843):514-516. PubMed ID: 33500573
[No Abstract] [Full Text] [Related]
2. Cancer: A most exceptional response.
Marx V
Nature; 2015 Apr; 520(7547):389-93. PubMed ID: 25877204
[No Abstract] [Full Text] [Related]
3. CRISPR screen in mechanism and target discovery for cancer immunotherapy.
Liu D; Zhao X; Tang A; Xu X; Liu S; Zha L; Ma W; Zheng J; Shi M
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188378. PubMed ID: 32413572
[TBL] [Abstract][Full Text] [Related]
4. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
5. Cancer: The Ras renaissance.
Ledford H
Nature; 2015 Apr; 520(7547):278-80. PubMed ID: 25877186
[No Abstract] [Full Text] [Related]
6. US Cancer Moonshot must strike a balance between research and prevention.
Nature; 2016 Nov; 539(7630):467. PubMed ID: 27882989
[No Abstract] [Full Text] [Related]
7. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
[TBL] [Abstract][Full Text] [Related]
8. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.
Dempster JM; Pacini C; Pantel S; Behan FM; Green T; Krill-Burger J; Beaver CM; Younger ST; Zhivich V; Najgebauer H; Allen F; Gonçalves E; Shepherd R; Doench JG; Yusa K; Vazquez F; Parts L; Boehm JS; Golub TR; Hahn WC; Root DE; Garnett MJ; Tsherniak A; Iorio F
Nat Commun; 2019 Dec; 10(1):5817. PubMed ID: 31862961
[TBL] [Abstract][Full Text] [Related]
9. The Future of Precision Oncology for the Treatment of Solid Tumors.
Klute KA
Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
[No Abstract] [Full Text] [Related]
10. Health: Make precision medicine work for cancer care.
Rubin MA
Nature; 2015 Apr; 520(7547):290-1. PubMed ID: 25877189
[No Abstract] [Full Text] [Related]
11. Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors.
Einama T; Kawamata F; Kamachi H; Nishihara H; Homma S; Matsuzawa F; Mizukami T; Konishi Y; Kamiyama T; Yamamoto J; Taketomi A; Todo S
EBioMedicine; 2017 Oct; 24():16-17. PubMed ID: 28965877
[No Abstract] [Full Text] [Related]
12. [MI-mAbs, pre-industrial demonstrator supported by PIA for the early validation of therapeutic targets using monoclonal antibodies].
Romagné F
Med Sci (Paris); 2019 Dec; 35(12):1202-1203. PubMed ID: 31903940
[No Abstract] [Full Text] [Related]
13. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
14. Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
Baretti M; Azad NS
Cancer J; 2019; 25(4):287-295. PubMed ID: 31335393
[TBL] [Abstract][Full Text] [Related]
15. Monkey kingdom.
Cyranoski D
Nature; 2016 Apr; 532(7599):300-2. PubMed ID: 27111614
[No Abstract] [Full Text] [Related]
16. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
17. Cancer immunotherapy: broadening the scope of targetable tumours.
van den Bulk J; Verdegaal EM; de Miranda NF
Open Biol; 2018 Jun; 8(6):. PubMed ID: 29875199
[TBL] [Abstract][Full Text] [Related]
18. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
19. Meeting Report: The 8th Barossa Meeting-Cell Signaling in Cancer Medicine in the Barossa Valley, Australia.
Gomez GA; Woodcock JM; Tergaonkar V; Gregory PA
Cell Death Dis; 2018 Feb; 9(3):284. PubMed ID: 29449550
[No Abstract] [Full Text] [Related]
20. Mutation and location important in cancer treatment.
Lewis R
Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
